ATE361745T1 - Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen - Google Patents
Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungenInfo
- Publication number
- ATE361745T1 ATE361745T1 AT02714977T AT02714977T ATE361745T1 AT E361745 T1 ATE361745 T1 AT E361745T1 AT 02714977 T AT02714977 T AT 02714977T AT 02714977 T AT02714977 T AT 02714977T AT E361745 T1 ATE361745 T1 AT E361745T1
- Authority
- AT
- Austria
- Prior art keywords
- carbamat
- compounds
- preventing
- neurodegenerative disorders
- treating neurodegenerative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168201P | 2001-02-27 | 2001-02-27 | |
| US10/081,764 US20020165273A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE361745T1 true ATE361745T1 (de) | 2007-06-15 |
Family
ID=26765943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02714977T ATE361745T1 (de) | 2001-02-27 | 2002-02-21 | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20020165273A1 (de) |
| EP (1) | EP1383489B1 (de) |
| JP (1) | JP4276840B2 (de) |
| KR (1) | KR100910928B1 (de) |
| CN (1) | CN1235579C (de) |
| AR (1) | AR035756A1 (de) |
| AT (1) | ATE361745T1 (de) |
| BR (1) | BR0207645A (de) |
| CA (1) | CA2439295C (de) |
| CY (1) | CY1106753T1 (de) |
| CZ (1) | CZ301203B6 (de) |
| DE (1) | DE60220043T2 (de) |
| DK (1) | DK1383489T3 (de) |
| ES (1) | ES2284845T3 (de) |
| HK (2) | HK1060516A1 (de) |
| HU (1) | HUP0303264A3 (de) |
| IL (2) | IL157591A0 (de) |
| MX (1) | MXPA03007718A (de) |
| MY (1) | MY138156A (de) |
| NO (1) | NO20033798L (de) |
| NZ (1) | NZ527990A (de) |
| PL (1) | PL364680A1 (de) |
| PT (1) | PT1383489E (de) |
| RS (1) | RS51055B (de) |
| RU (1) | RU2300373C2 (de) |
| TW (1) | TWI312679B (de) |
| WO (1) | WO2002067925A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2580584C (en) * | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
| ATE464044T1 (de) * | 2004-09-16 | 2010-04-15 | Janssen Pharmaceutica Nv | Verwendung von 2-phenyl-1,2-ethanediol- (di)carbamaten zur behandlung von epileptogenese |
| EA200700871A1 (ru) * | 2004-10-15 | 2007-10-26 | Янссен Фармацевтика Н. В. | Способы нейропротекции |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| KR101199499B1 (ko) * | 2005-07-26 | 2012-11-09 | 얀센 파마슈티카 엔.브이. | 물질 관련 장애를 치료하는 방법 |
| EA200970355A1 (ru) * | 2006-10-06 | 2009-12-30 | Янссен Фармацевтика Нв | Новый кристалл (s)-(+)-2-(2-хлорфенил)-2-гидроксиэтилкарбамата |
| EP2081648A2 (de) * | 2006-10-30 | 2009-07-29 | Janssen Pharmaceutica, N.V. | Carbamatverbindungen zur verwendung bei der behandlung von depressionen |
| EA200970435A1 (ru) * | 2006-10-31 | 2009-10-30 | Янссен Фармацевтика, Н. В. | Лечение общих расстройств развития |
| BR112013000050B1 (pt) * | 2010-07-02 | 2021-10-19 | Bio-Pharm Solutions Co., Ltd | Compostos de carbamato de fenila e composição farmacêutica |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| WO2013036678A1 (en) * | 2011-09-07 | 2013-03-14 | Satori Pharmaceuticals, Inc. | Compounds useful for treating neurodegenerative disorders |
| CA2858977C (en) * | 2011-12-27 | 2020-06-23 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in alleviating or treating pain |
| US9566261B2 (en) | 2013-03-12 | 2017-02-14 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same |
| CN109939092B (zh) | 2013-03-12 | 2022-03-22 | 比皮艾思药物研发有限公司 | 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物 |
| BR112018067663B1 (pt) * | 2016-02-29 | 2023-01-10 | Bio-Pharm Solutions Co., Ltd | Compostos derivados de sulfamato, seus usos e composição farmacêutica |
| US11147798B2 (en) | 2016-12-14 | 2021-10-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| JP7408643B2 (ja) * | 2018-09-21 | 2024-01-05 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用 |
| EP4204395A4 (de) * | 2020-08-31 | 2024-08-07 | Bio-Pharm Solutions Co., Ltd. | Phenylalkylcarbamatverbindungen zur verwendung bei der vorbeugung oder behandlung von neurodegenerativen erkrankungen |
| JP7648746B2 (ja) | 2020-09-10 | 2025-03-18 | バイオ－ファーム ソリューションズ カンパニー リミテッド | 精神疾患の治療又は軽減のためのスルファメート誘導体化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3278380A (en) * | 1962-02-06 | 1966-10-11 | Armour Pharma | Methods of calming employing diphenyl hydroxy carbamate compounds |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5474990A (en) * | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
| US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| CZ302412B6 (cs) * | 2001-02-27 | 2011-05-04 | Ortho-Mcneil Pharmaceutical, Inc. | Lécivo pro prevenci nebo lécbu psychotických chorob |
| CZ20032300A3 (cs) * | 2001-02-27 | 2005-01-12 | Ortho-Mcneil Pharmaceutical, Inc. | Léčivo pro prevenci nebo léčbu bipolárních chorob |
| IL157592A0 (en) * | 2001-02-27 | 2004-03-28 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing or treating movement disorders |
-
2002
- 2002-02-21 MX MXPA03007718A patent/MXPA03007718A/es active IP Right Grant
- 2002-02-21 DE DE60220043T patent/DE60220043T2/de not_active Expired - Lifetime
- 2002-02-21 PT PT02714977T patent/PT1383489E/pt unknown
- 2002-02-21 IL IL15759102A patent/IL157591A0/xx unknown
- 2002-02-21 KR KR1020037011302A patent/KR100910928B1/ko not_active IP Right Cessation
- 2002-02-21 DK DK02714977T patent/DK1383489T3/da active
- 2002-02-21 CN CNB028087178A patent/CN1235579C/zh not_active Expired - Fee Related
- 2002-02-21 EP EP02714977A patent/EP1383489B1/de not_active Expired - Lifetime
- 2002-02-21 RU RU2003128982/14A patent/RU2300373C2/ru not_active IP Right Cessation
- 2002-02-21 US US10/081,764 patent/US20020165273A1/en not_active Abandoned
- 2002-02-21 WO PCT/US2002/005541 patent/WO2002067925A1/en active IP Right Grant
- 2002-02-21 ES ES02714977T patent/ES2284845T3/es not_active Expired - Lifetime
- 2002-02-21 RS YUP-674/03A patent/RS51055B/sr unknown
- 2002-02-21 PL PL02364680A patent/PL364680A1/xx unknown
- 2002-02-21 JP JP2002567292A patent/JP4276840B2/ja not_active Expired - Fee Related
- 2002-02-21 AT AT02714977T patent/ATE361745T1/de active
- 2002-02-21 HU HU0303264A patent/HUP0303264A3/hu unknown
- 2002-02-21 CZ CZ20032313A patent/CZ301203B6/cs not_active IP Right Cessation
- 2002-02-21 NZ NZ527990A patent/NZ527990A/en unknown
- 2002-02-21 BR BR0207645-4A patent/BR0207645A/pt not_active Application Discontinuation
- 2002-02-21 CA CA2439295A patent/CA2439295C/en not_active Expired - Fee Related
- 2002-02-27 MY MYPI20020697A patent/MY138156A/en unknown
- 2002-02-27 AR ARP020100697A patent/AR035756A1/es unknown
- 2002-02-27 TW TW091103504A patent/TWI312679B/zh active
-
2003
- 2003-08-26 NO NO20033798A patent/NO20033798L/no not_active Application Discontinuation
- 2003-08-26 IL IL157591A patent/IL157591A/en not_active IP Right Cessation
-
2004
- 2004-03-10 US US10/797,795 patent/US20040171679A1/en not_active Abandoned
- 2004-05-17 HK HK04103497A patent/HK1060516A1/xx not_active IP Right Cessation
- 2004-10-26 HK HK04108387A patent/HK1065486A1/xx not_active IP Right Cessation
-
2007
- 2007-07-24 CY CY20071100982T patent/CY1106753T1/el unknown
-
2008
- 2008-09-10 US US12/207,816 patent/US20090005442A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE361745T1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen | |
| DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| DE60102016D1 (de) | Verfahren zur behandlung von beweggungsstörungen | |
| EP1534074A4 (de) | Kombinationstherapie zur behandlung von fettleibigkeit | |
| EP1274444A4 (de) | Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen | |
| ATE515261T1 (de) | Zusammensetzungen zur behandlung von diabetes | |
| DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| ATE369130T1 (de) | Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen | |
| DE60233186D1 (de) | Verbessertes System zur Behandlung von Elementarschwefel-Rückständen | |
| DE69925865D1 (de) | 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE502004010131D1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
| DE60327074D1 (de) | Fluorobenzamide zur behandlung von alzheimer oder seniler dementia | |
| ATE493125T1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
| DE60223688D1 (de) | Verfahren zur behandlung von multiplem myelom | |
| DE60101309D1 (de) | Diacerein zur behandlung von psoriasis | |
| DE69943089D1 (de) | Methode zur behandlung von staphylokokkeninfektionen | |
| DE69941821D1 (de) | Fluorenthaltende zusammensetzung zur behandlung von oberflächen | |
| DE602004019576D1 (de) | Zur behandlung von schmerzen geeignete piperazine | |
| DE60214355D1 (de) | Exemestan zur behandlung von hormonabhängigen störungen | |
| DE60224650D1 (de) | Vorrichtung zur behandlung von vorhof-fibrillation | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| DE60223718D1 (de) | Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1383489 Country of ref document: EP |